Table 2.
Role of circulating microRNAs in response to therapies of breast cancer subtypes.
| MicroRNAs | Expression Level/Prognostic Value | Reference |
|---|---|---|
| miR-19a, -205 | Up-regulated in chemotherapy resistant compared to sensitive Luminal A cases | [70] |
| miR-21, -210, -373 | Higher in HER2+ cases, before and after neoadjuvant therapy (chemotherapy combined to trastuzumab/lapatinib), compared to controls | [71] |
| miR-720, -4716-5p, -17-3p, -451a, -16-5p, -451b, -940, -10b-3p, -30b-3p, -4310, -494, -22-3p, -29a-5p | Differentially expressed in metastatic HER2+ cases in relation to trastuzumab response | [72] |
| miR-940, -451a, -16-5p, -17-3p | Predictors of trastuzumab sensitivity in metastatic HER2+ cases | |
| miR-21 | Decreased level in HER+ cases after trastuzumab treatment: prognostic and predictive factor of trastuzumab response | [73] |
| miR-21, -105 | Increased level in pre-neoadjuvant chemotherapy metastatic BC cases compared to non-metastatic cases and controls | [74] |
| miR-200b, -135b, -29a | Up-regulated in HER2+ trastuzumab-resistant cases | [75] |
| miR-224 | Down-regulated in HER2+ trastuzumab-resistant cases | |
| miR-21 | Predictor of therapy response (neoadjuvant chemotherapy plus trastuzumab) in HER2+ cases | [76] |
| miR-17, -19b, -30b | Predictors of response to neoadjuvant chemotherapy in TNBC cases | [77] |
| miR-21, -195. -145 | Predictors of response to neoadjuvant chemotherapy in Luminal BC cases | [78] |
Abbreviations: +, positive; -, negative; BC, breast cancer; TNBC, triple negative breast cancer.